跳至主要内容
临床试验/TCTR20231106002
TCTR20231106002招募中4 期

Efficacy of 5% Trisodium Citrate and Low Dose Heparin as Catheter-Locking Solution for Central Venous Hemodialysis Catheters: A Randomized Controlled Study

Thammasat University Research Fund0 个研究点目标入组 216 人开始时间: 2023年11月6日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
216

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 90 Years(—)
性别
All

入选标准

  • 1. Hemodialysis patients, 2. Well-positioned of non-tunnel cuffed catheter (NTCC) or tunnel cuffed catheter (TCC) expected to be needed for more than 1 week without flow problems (a persistent inability to obtain blood flow rate [BFR] above 250 mL/minute)

排除标准

  • 1. Hemorrhagic diathesis conditions (liver failure, disseminated intravascular coagulopathy, leukemia, vitamin K deficiency, hemophilia, or thrombocytopenia), 2. Hypercoagulable states (deep vein thrombosis, pulmonary embolism, or antiphospholipid syndrome), 3. Hematologic diseases (paroxysmal nocturnal hemoglobinuria, myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis, or hemolytic anemia), 4. Metastatic cancer, 5. Currently using of oral contraceptive pills, 6. Currently using one of the following anticoagulants: warfarin, UFH, enoxaparin, rivaroxaban, apixaban, or dabigatran, 7. Proven or suspected heparin induced thrombocytopenia, 8. Allergic to UFH or TSC, 9. Pregnant, 10. Unable to obtain crucial data, 11. Refused to participate

研究者

发起方
Thammasat University Research Fund

相似试验